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Introduction: Acute respiratory failure (ARF) is the main reason for intensive care unit (ICU) admissions in patients
with hematologic malignancies (HMs). We report the first series of adult patients with ARF and HMs treated with
extracorporeal membrane oxygenation (ECMO).
Methods: This is a retrospective cohort study of 14 patients with HMs (aggressive non-Hodgkin lymphoma (NHL)
n = 5; highly aggressive NHL, that is acute lymphoblastic leukemia or Burkitt lymphoma, n = 5; Hodgkin lymphoma,
n = 2; acute myeloid leukemia, n = 1; multiple myeloma, n = 1) receiving ECMO support because of ARF (all data as
medians and interquartile ranges; age, 32 years (22 to 51 years); simplified acute physiology score II (SAPS II): 51
(42 to 65)). Etiology of ARF was pneumonia (n = 10), thoracic manifestation of NHL (n = 2), sepsis of nonpulmonary
origin (n = 1), and transfusion-related acute lung injury (n = 1). Diagnosis of HM was established during ECMO in
four patients, and five first received (immuno-) chemotherapy on ECMO.
Results: Before ECMO, the PaO2/FiO2 ratio was 60 (53 to 65), (3.3 to 3.7). Three patients received venoarterial ECMO
because of acute circulatory failure in addition to ARF; all other patients received venovenous ECMO. All patients
needed vasopressors, and five needed hemofiltration. Thrombocytopenia occurred in all patients (lowest platelet
count was 20 (11 to 21) G/L). Five major bleeding events were noted. ECMO duration was 8.5 (4 to 16) days. ICU
and hospital survival was 50%. All survivors were alive at follow-up (36 (10 to 58) months); five patients were in
complete remission, one in partial remission, and one had relapsed.
Conclusions: ECMO therapy is feasible in selected patients with HMs and ARF and can be associated with long-term
disease-free survival.Introduction
The acute respiratory failure (ARF) represents the pre-
dominant reason for medical intensive care unit (ICU)
admissions in patients with hematologic malignancies
(HMs) [1-5]. Its occurrence has a strong prognostic
impact, especially if mechanical ventilation becomes
necessary. Although the outcome of those affected was* Correspondence: peter.schellongowski@meduniwien.ac.at
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stated.described to be dismal in the past, survival improved
markedly in recent years. This development may be
attributed to advances in patient selection [6], general
improvements in the management of the acute respi-
ratory distress syndrome (ARDS), as well as specific
improvements in managing ARF in patients with HMs.
The latter comprises specific diagnostic algorithms in
ARF of HM patients [7], as well as the use of nonin-
vasive ventilation early in the course, even though the
efficacy of this procedure does not remain undisputed
[8-11]. However, mortality rates of patients with HMsral Ltd. This is an Open Access article distributed under the terms of the Creative
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ceed 50% [1,3-5]. Yet, a general reluctance to admit crit-
ically ill patients with HMs cannot be justified.
Unlimited intensive care has been advocated for selected
patients with HMs [12,13].
The extracorporeal membrane oxygenation (ECMO) de-
picts one of the ultimate therapies in intensive care and
may possibly be beneficial in patients with ARDS in gen-
eral ICU populations [14,15]. Some data exist on the use
of ECMO in cohorts of children with malignant diseases
[16,17], but the published experience with ECMO in adult
patients with HM is limited to two single cases [18,19].
Because both, patients with HMs and those undergoing
ECMO are prone to acquire severe complications, such as
bleeding and infection [1,5,20-23], performing ECMO in
patients with HMs might bear a particularly high risk.
The purpose of this analysis is to report the characteris-
tics and outcomes of patients with HMs and ARF treated
with ECMO.
Materials and methods
We retrospectively studied the clinical courses of all
adult patients (18 years or older) with HMs and ARF
treated with ECMO at the Medical University of Vienna,
General Hospital, between September 2000 and June
2013. This study was conducted in accordance with the
amended Declaration of Helsinki. The ethics committee
of the Medical University of Vienna approved the proto-
col and waived the need for informed consent because
of the noninterventional retrospective design of the
investigation.
The presence of ARDS was defined and graded ac-
cording to recently introduced criteria [24]. The term
baseline refers to the time immediately before the start
of ECMO treatment. Thrombocytopenia was defined
as platelet count <150 G/L, and leukocytopenia as
leukocyte count <4 G/L.
In our center, extracorporeal lung support is usually
evaluated in patients presenting with severe and life-threat-
ening hypoxemia while being mechanically ventilated with
adequately high positive end-expiratory pressure (PEEP)
and a missing response to supportive measures like prone
positioning. During ECMO, a maximally achievable pro-
tective ventilation setting is desired. Weaning from ECMO
is performed according to current Extracorporeal Life
Support Organization (ELSO) guidelines [25].
At baseline, we recorded age, gender, characteristics of
the hematologic malignancy, including type and stage of
the respective malignancy, time of diagnosis, type and
timing of previous specific treatments (that is, chemo-,
immuno-, or radiotherapy, autologous or allogeneic stem
cell transplantation (ASCT)), as well as the intention of
cancer treatment (curative versus noncurative). The
Charlson Comorbidity Index [26] (CCI) was assessed toaccount for comorbid conditions. To grade the severity
of illness, we calculated the Simplified Acute Physiology
Score II (SAPS II) [27,28] at ICU admission, as well as
the Sequential Organ Failure Assessment (SOFA) score
[29] at baseline, respectively. We determined the etio-
logy of ARF and recorded arterial blood gas parameters
(pH, partial pressures of oxygen (PaO2) and carbon diox-
ide (PaCO2), lactate), PaO2/FiO2 ratio, the Lung Injury
Score (LIS) [30], laboratory tests such as white blood cell
count, platelet count, hemoglobin, prothrombin time,
and fibrinogen, all at baseline, eventually.
As follow-up variable, we recorded type of ECMO
(that is, venovenous (VV) versus venoarterial (VA), use
of anticoagulants, vasopressors, and blood products,
duration of ECMO therapy, length of ICU and hospital
stay, bleeding complications (occurrence, location, and
severity), other procedure-related complications (trauma
or bleeding related to the insertion of cannulas, clotting
events), ICU and hospital survival, course of the malig-
nancy (remission status), death date (if applicable), as well
as date of the last visit. Bleeding was considered to be
major in patients with a decrease in hemoglobin levels
>2.0 g/dl or requiring more than 2 units of packed red
blood cells due to an obvious bleeding event, surgical
interventions, or in cases of intracerebral hemorrhage. In
patients with more than one episode of ECMO, baseline
parameters and definite outcomes associated with the last
respective ECMO episode were analyzed, whereas for cal-
culation of total ECMO days, all episodes were counted.
Continuous data are presented as median and interquar-
tile ranges (25% to 75%), unless otherwise indicated. Di-
chotomous data are presented as number and percentage.
Data were compared between survivors and nonsurvivors
with Fisher Exact test for dichotomous variables, and the
Mann–Whitney U Test for continuous variables, respect-
ively. Differences were considered to be statistically signifi-
cant when P was <0.05.
Results
We report on 14 consecutive patients with HMs and
ARF treated a total number of 17 ECMO episodes. The
male/female ratio was 8:6, age 32 years (22 to 51 years),
CCI 2 (2 to 2) and SAPS II 51 (42 to 65), respectively.
The individual characteristics of patients (numbers 1 to 14)
are given in Table 1. During the observational period, 541
patients with HMs were admitted to our ICU, of whom
368 (68%) presented with respiratory failure requiring
invasive mechanical ventilation. Thus, the proportion
of HM patients with ARF receiving ECMO therapy
was 3.8%.
Hematologic malignancy
The underlying HMs were various types of aggressive
non-Hodgkin lymphoma (NHL) in five patients (diffuse
Table 1 Individual characteristics and outcomes




SAPS II LIS ECMO days Bleeding ICU and hospital
outcome
1 CNS NHL Chemotherapy (51) Pneumonia 45 3.7 9 Minor Died
2 Hodgkin lymphoma Allo SCT (111) Pneumonia 34 3.3 28b Major Died
3 ALL Consolidation (13) Abdominal sepsis 78 2.3 4c - Alive
4 ALLa Induction on ECMO TRALI 62 3.3 3 - Alive
5 Burkitt lymphoma Induction (16) Pneumonia 63 3.8 8 - Alive
6 ALL Allo SCT (31) Pneumonia 39 3.5 7 Major Died
7 Hodgkin lymphoma Allo SCT (33) Pneumonia 65 3.3 18 - Died
8 ALL Allo SCT (203) Pneumonia 68 3.3 10 - Died
9 DLBCL Induction on ECMO Pneumonia 102 4.0 4 - Died
10 Multiple myeloma Auto SCT (789) Pneumonia 43 3.7 9 Major Alive
11 Anaplastic T-cell NHLa Induction on ECMO Pneumonia 46 3.0 25d Major Alive
12 DLBCLa Induction on ECMO NHL 36 3.3 3c - Alive
13 AML Consolidation (34) Pneumonia 48 3.3 34 Major Died
14 DLBCLa Induction on ECMO NHL 56 2.3 4d - Alive
ALL, acute lymphoblastic leukemia; allo SCT, allogeneic stem cell transplantation; AML, acute myeloid leukemia; ARF, acute respiratory failure; auto SCT,
autologous stem cell transplantation; CNS, central nervous system; DLBCL, diffuse large B-cell lymphoma; ECMO, extracorporeal membrane oxygenation; ICU,
intensive care unit; LIS, lung injury score at ECMO baseline [30]; NHL, non-Hodgkin lymphoma; SAPS II, simplified acute physiology score at ICU admission [27];
TRALI, transfusion-related acute lung injury. aDiagnosis of hematologic malignancy on ECMO; bTwo episodes of ECMO; cventoarterial ECMO; dthree episodes
of ECMO.
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oma, n = 1; central nervous system NHL, n = 1), highly
aggressive NHL in five (acute lymphoblastic leukemia,
n = 4 and Burkitt lymphoma, n = 1), Hodgkin lymph-
oma in two, as well as acute myeloid leukemia and mul-
tiple myeloma in one patient each, respectively. The
diagnosis of HM was established during ECMO support
in four patients (patients 4, 11, 12, and 14). Five patients
first received (immuno-) chemotherapy on ECMO, and
four patients had recently received chemotherapy. Four
patients had undergone ASCT within the previous year.
Overall, seven patients were in the induction phase, six
were in remission since 96 days (range, 39 to 292; patients
2, 3, 6 to 8, and 13), and the patient with multiple mye-
loma was in partial remission. All patients but the latter
had curative therapeutic options regarding their under-
lying HMs. For further information, see Table 1.
Etiology of acute respiratory failure
Etiology of ARF was pneumonia (n = 10), massive thor-
acic bulky disease with partial obstruction of bronchi,
intrathoracic vessels, and the right heart (n = 2), as well
as sepsis of nonpulmonary (abdominal) origin (n = 1),
and transfusion-related acute lung injury (n = 1), respect-
ively. Twelve patients fulfilled the criteria of severe
ARDS. Microbiologic workup revealed pathogenic orga-
nisms in only three patients: Influenza A H1N1 (n = 2,
patients 10 and 13) as well as histologically proven cyto-
megalovirus (CMV) infection (n = 1, patient 8). In two
further patients, CMV infection was considered possible(massive replication of CMV copies in bronchoalveolar
lavage fluid and plasma, patients 1 and 7). Diagnostic
biopsies were performed on ECMO in five patients and
revealed NHL (n = 2), CMV pneumonia (n = 1), and in-
conclusive results (n = 2). Autopsy was performed in five
patients but did not reveal any further information on
specific pathology or infections.
Baseline characteristics
At baseline, the median SOFA score was 12 (11 to 13),
and LIS was 3.3 (3.3 to 3.7). All patients were receiving
vasopressors, and one patient underwent continuous veno-
venous hemofiltration. Thrombocytopenia was present in
11 patients, with a median platelet count of 35 (26 to 51)
G/L, and leukocytopenia was present in five patients with a
median leukocyte count of 2.1 (1.8 to 2.5) G/L.
ECMO therapy
At the discretion of the treating intensivist, all but three
patients were placed in the prone position before the
start of VV ECMO. Decision for ECMO was then taken
if the patient was still severely hypoxemic, or if ventila-
tion was still unacceptably invasive.
Three patients received VA ECMO because, in addition
to ARF, they presented with severe circulatory failure due
to septic cardiomyopathy, leading to refractory left
ventricular failure in one patient (patient 3) and life-
threatening right ventricular failure in two patients,
one of them with an acute subtotal occlusion of the right
pulmonary artery (patient 12), and one of them with acute
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heart due to DLBCL masses (patient 14).
All other patients received VV ECMO because of
severe ARDS only. In one patient with a recent history
of ASCT, ECMO was started before invasive mechanical
ventilation with the intention of preventing intubation
(patient 7). However, the patient had to be intubated on
the subsequent day. ECMO therapy was used for a me-
dian of 8.5 (4 to 16) days, and mechanical ventilation,
for 17 (12 to 35) days.
In patients with VV ECMO, percutaneous cannulation
was performed by inserting a 21- to 24-F drainage
cannula into a femoral vein and a 19- to 22-F into the right
jugular vein by using the ultrasound-guided Seldinger
technique. In one patient (patient 7), a 31-F double-lumen
cannula was placed into the right jugular vein. In all three
patients with VA ECMO, venous drainage cannulas were
placed into a femoral vein, whereas the blood was returned
via a femoral artery in two patients and via a right-sided
subclavian patch in one patient (patient 12). Cannulation
in VA ECMO was performed surgically by using a semi-
Seldinger cutdown technique. Sweep gas flow was set to
achieve sufficient CO2 elimination, and the blood flow was
set to achieve adequate systemic oxygenation or adequate
circulatory support in VA ECMO patients.
Eleven patients received continuous intravenous infu-
sion of unfractionated heparin to maintain an activated
partial thromboplastin time of approximately 55 seconds.
All but two of these patients additionally received anti-
platelet therapy by intravenous prostaglandin E1 at doses
of 2.5 to 5 ng/kg/min. Three patients received subcuta-
neous low-molecular-weight heparin alone.
Interventional procedures
Both patients with circulatory failure due to massive
intra-thoracic DLBCL masses were treated by interven-
tional radiologists under emergency conditions on VA
ECMO. The patient who presented with acute obstruct-
ive circulatory failure due to a highly compressed right
pulmonary artery (patient 12) was treated with percutan-
eous implantation of a 16 × 40-mm self-expanding nit-
inol stent (sinus-XL; Optimed Medizinische Instrumente
GmbH, Ettlingen, Germany) into the mainstem of the
pulmonary artery. In the patient with severe superior
vena cava (SVC) syndrome (patient 14) a 24 × 60-mm
sinus-XL stent was placed into the SVC by a transjugular
access. In both patients, stent placement led to an imme-
diate restoration of blood flows and, eventually, complete
recovery of the circulatory failure.
Bleeding events and other complications
Major bleeding events were documented in five (36%)
patients from these locations: upper gastrointestinal tract
(n = 3), nasopharynx, lung, and cannula insertion site (allin one patient), and multilocular intracerebral hemor-
rhages (n = 1). Of these, only the latter patient survived
and experienced full neurologic recovery after discharge.
In the four nonsurvivors, bleeding was part of multiorgan
failure and not the primary reason for death. One patient
with septic cardiomyopathy developed severe dissemi-
nated intravascular coagulation, leading to limb ischemia,
and eventually needed amputation of both lower and one
upper extremity. No thrombotic events were noted in any
other patient (Table 1).
Comparison of survivors with nonsurvivors
Survivors had a significantly shorter time interval from
diagnosis of the HM to the start of ECMO therapy,
received less packed red blood cell units as well as
single-donor platelet concentrates, and were less likely
to have a history of ASCT. A trend for higher survival
rates was noted in patients with shorter time intervals
between ICU admission and start of ECMO therapy,
shorter ECMO duration, and in patients in whom diag-
nosis of HM was made on ECMO. Conversely a trend
for lower survival rates was noted in patients with higher
LIS scores or PaCO2 levels at baseline, and in those with
clinical signs of pneumonia (Table 2).
Survival and hematologic outcome
Survival off ECMO episodes was 59% (10/17). One of
the two patients with multiple episodes of ECMO sur-
vived and was discharged after the third application of
ECMO, whereas the other patient died during the sec-
ond ECMO episode. All patients with a history of ASCT
died. Seven (50%) patients survived the ICU and hospital
stay. Their long-term survival was 100% after a median
follow-up of 36 (10 to 58) months. At the time of the
last visit, five survivors were in complete remission of
their HM, whereas the patient with multiple myeloma
remained in partial remission, and one patient with ana-
plastic T-cell lymphoma had experienced relapse. All but
one patient in need of further antineoplastic treatment
received the regularly scheduled number of chemotherapy
courses without dose reduction.
Discussion
Recent data show impressive improvements in the out-
comes of critically ill patients with HMs [1]. However,
mortality rates still remain at >50%, if invasive me-
chanical ventilation becomes necessary because of ARF
[1,2,4,5,9]. Thus, novel strategies to treat these patients
are desperately needed. This is the first report on the
use of ECMO in a series of patients with HMs and ARF.
We observed a remarkable short- and long-term survival
of 50%, despite the presence of numerous factors known
to be associated with adverse outcome [13]: First, all
patients presented with at least three organ failures. Second,
Table 2 Cohort characteristics and outcomes
All patients N = 14 Survivors n = 7 Nonsurvivors n = 7 P value
Characteristics at ICU admission
Age 32 (22–51) 23 (21–44) 48 (30–58) 0.14
Male sex 8 4 4 1.00
CCI 2 (2–2) 2 (2–2) 2 (2–4) 0.48
SAPS II 51 (42–65) 56 (43–63) 45 (39–68) 0.90
Prior allogeneic stem cell transplantation 4 0 4 <0.01
Days from diagnosis of HM to ECMO 87 (6–907) 0 ((−1)–116) 759 (69–1,228) 0.04
Days from ICU admission to ECMO 2 (0–3) 1 (0–2) 3 (1–11) 0.08
Days from intubation to ECMO 2 (1–5) 1 (0–2) 3 (1–9) 0.17
Characteristics at ECMO baseline
SOFA score 12 (11–13) 12 (12–19) 12 (11–15) 0.79
Lung injury score 3.3 (3.3–3.7) 3.3 (2.3–3.7) 3.5 (3.3–3.8) 0.09
PaO2/FiO2 ratio 60 (53–65) 63 (51–106) 60 (48–61) 0.44
pH 7.29 (7.23–7.37) 7.29 (7.23–7.39) 7.37 (7.21–7.46) 0.52
PaCO2, mm Hg 49 (43–59) 41 (38–49) 55 (48–72) 0.05
Lactate, mM 2.2 (1.6–4.8) 3.8 (1.6–7.1) 2.0 (1.0–5.0) 0.34
Hemoglobin, g/dl 9.4 (8.8–10.4) 9.4 (8.6–10.5) 9.8 (8.4–10.4) 0.90
Leukocytes, G/L 6.0 (2.5–12.6) 11.0 (3.6–17.0) 5.6 (2.0–12.8) 0.34
Platelets, G/L 38 (30–113) 64 (29–201) 35 (10–88) 0.21
Prothrombin time, % 70 (43–74) 50 (18–72) 73 (64–78) 0.22
Fibrinogen, mg/dl 436 (220–522) 473 (160–627) 421 (294–531) 1.00
Etiology of ARF determineda 7 5 2 0.29
Clinical diagnosis of pneumonia 10 3 7 0.07
Characteristics during ECMO
Venoarterial ECMO 3 3 0 0.19
Duration of ECMO therapy, days 8.5 (4–16) 4 (3–9) 10 (7–28) 0.08
Diagnosis of HM on ECMO 4 4 0 0.07
Chemotherapy on ECMO 5 4 1 0.27
Vasopressors 14 7 7 na
Hemofiltration 5 2 3 1.00
Major bleeding events 5 1 4 0.27
Number of packed red blood cell units 8 (4–14) 4 (3–8) 14 (6–27) 0.02
Number of platelet concentrates 5 (1–17) 2 (0–5) 23 (14–26) 0.01
Outcome
ICU LOS, days 22 (14–42) 22 (21–77) 18 (11–40) 0.12
Hospital LOS, days 56 (44–101) 63 (49–110) 45 (15–133) 0.46
ICU and hospital survival, n (%) 7 (50%)
Data are given as median and interquartile range or n, respectively; ARF, acute respiratory failure; CCI, Charlson comorbidity index [26]; HM, hematologic
malignancy; ICU, intensive care unit; ECMO, extracorporeal membrane oxygenation; LOS, length of stay; na, not applicable; SAPS II, Simplified Acute Physiology
Score at ICU admission [27]; SOFA score, Sequential Organ Failure Assessment Score at ECMO Baseline [29]; amicrobiologic pathogen detected or histologic proof
of HM in lung biopsy.
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to identify causative pathogens in almost all patients with
pneumonia. Third, four (29%) patients had undergone
ASCT within the previous year. The finding that all fourpatients with a history of ASCT died, underlines the
negative prognostic impact of allogeneic stem cell
transplantation in critical illness. However, two of our pa-
tients may not have been good candidates for aggressive
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ease and thrombotic microangiopathy, which is known to
be associated with poor outcome [31,32]. All of the 10
remaining patients fulfilled the criteria for a full-code ICU
management, as recently proposed by an international
expert consensus on critically ill cancer patients [13]. Their
long-term survival was 70% even in the presence of multi-
organ failure, severe and persistent thrombocytopenia,
and/or leukocytopenia, multiple episodes of ECMO, the
administration of chemotherapy, or other complex inter-
ventions before or during ECMO. Moreover, all but one
surviving patient had favorable hematologic outcomes
during the follow-up period.
The high rate of severe bleeding events (five (36%) of 14)
raises concerns about the safety of ECMO in patients with
persistent thrombocytopenia. Importantly, four of five
bleeding events occurred in the context of terminal multi-
organ failure and were not likely to be the primary cause of
death. However, according to our experience, keeping
platelet count above the recommended threshold of 80 G/L
[25] does not seem to be feasible in most patients with
HMs. Thus, avoiding any additional risk factors for bleed-
ing seems of major interest. We refrained from using any
anticoagulation therapy for a total of 14 days in one
persistently thrombocytopenic patient by using a
heparin-coated system (HLS Set Advanced 7.0, Maquet
Cardiopulmonary AG, Rastatt, Germany). The gas ex-
change remained excellent during the whole period, and
no signs of hemolysis or coagulation activation were
noted. To minimize the risk of bleeding in patients refrac-
tory to platelet transfusions, we suggest considering a “low
or no” strategy concerning anticoagulation.
This study has several limitations. First, the retrospect-
ive design of the investigation does not allow conclusions
concerning the efficacy of ECMO in these patients.
Second, the number of patients is small. Third, our data
reflect the experience of a single institution specifically
devoted to the treatment of critically ill cancer patients
and patients with ARDS, including extracorporeal lung
support. Furthermore, it must be acknowledged that our
cohort of patients represents only a very small proportion
of critically ill HM patients with respiratory failure. Thus,
our series is highly selective, and our findings may not be
generalized.
Despite the promising results of our report, apply-
ing ECMO to patients with HMs cannot be regarded
as an established therapy. Its efficacy and associated
risks still remain to be established. Further research
should focus on following questions: Which patients
are likely to benefit from ECMO? When and under which
circumstances should ECMO be initiated? What are the
possible risks apart from complications associated with
cannulation, infections, and bleeding events? Which mea-
sures must be taken to make ECMO as safe as possible inthese vulnerable patients? Can ECMO be safely performed
in spontaneously breathing patients with HMs and ARF to
prevent endotracheal intubation?
Until these issues are settled, we propose to apply
ECMO to patients with HMs exclusively under the follow-
ing circumstances: (a) patients qualify for a full-code ICU
management according to current recommendations on
critically ill cancer patients [13], (b) lung-protective venti-
lation strategies, including supportive measures like prone
positioning, result in inadequate gas exchange [24,33], (c)
patients are included into yet to establish prospective
research protocols, (d) a close cooperation of intensivists,
hematologists, vascular surgeons, and perfusionists (if part
of the local standard) is warranted, (e) general guidelines
for the management of patients on ECMO are available
and being followed [25], and (e) issues concerning antic-
oagulation and platelet transfusion are considered with
special respect.
Conclusions
In conclusion, performing ECMO in carefully selected
patients with HMs and severe ARF can be associated with
favorable short- and long-term survival. This finding may
even apply to patients with multiorgan failure, severe cyto-
penia, newly diagnosed HMs, as well as to those who need
chemotherapy or complex interventional procedures on
ECMO.
Key messages
 ECMO is feasible in patients with hematologic
malignancies and acute respiratory failure.
 These patients are at increased risk for severe
bleeding events.
 Short- and long-term survival may be significant
in selected patients.
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